Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

36.83
-0.1500-0.41%
Post-market: 36.10-0.7300-1.98%19:30 EDT
Volume:3.90M
Turnover:143.77M
Market Cap:1.79B
PE:-18.70
High:38.11
Open:36.97
Low:36.69
Close:36.98
52wk High:50.81
52wk Low:15.86
Shares:48.68M
Float Shares:43.35M
Volume Ratio:3.78
T/O Rate:8.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9700
EPS(LYR):-3.1901
ROE:-1481.26%
ROA:-18.06%
PB:-13.54
PE(LYR):-11.55

Loading ...

Mar 02, 2026

Major Issues Report

Form 8-K - Current report
Mar 02, 2026

Major Issues Report

Form 8-K - Current report
Feb 03, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 19, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 06, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 06, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 06, 2025

Major Issues Report

Form 8-K - Current report
Sep 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 27, 2025

Major Issues Report

Form 8-K - Current report
Aug 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2025

Major Issues Report

Form 8-K - Current report
Jul 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 03, 2025

Major Issues Report

Form 8-K - Current report
Jun 13, 2025

Major Issues Report

Form 8-K - Current report
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 12, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2025

Major Issues Report

Form 8-K - Current report
May 01, 2025

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]